Fuji Pharma Co
Fuji Pharma Co., Ltd., commonly referred to as Fuji Pharma, is a prominent player in the pharmaceutical industry, headquartered in Japan. Established in 1950, the company has made significant strides in developing innovative healthcare solutions, primarily focusing on prescription pharmaceuticals and over-the-counter products. With a strong operational presence across Asia, Fuji Pharma is renowned for its commitment to quality and research-driven development. The company’s core offerings include a diverse range of therapeutic agents, particularly in the fields of oncology and infectious diseases, distinguished by their efficacy and safety profiles. Fuji Pharma has garnered recognition for its robust market position, consistently achieving milestones that underscore its dedication to advancing healthcare. Through a combination of cutting-edge technology and a patient-centric approach, Fuji Pharma continues to enhance its reputation as a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does Fuji Pharma Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Fuji Pharma Co's score of 39 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Fuji Pharma Co's reported carbon emissions
In 2022, Fuji Pharma Co., headquartered in Japan, reported total carbon emissions of approximately 306,558,000 kg CO2e. This figure includes 6,044,000 kg CO2e from Scope 1 emissions, 8,153,000 kg CO2e from Scope 2 emissions, and a significant 292,361,000 kg CO2e from Scope 3 emissions. This represents a substantial increase from 2021, when total emissions were about 12,514,000 kg CO2e, with Scope 1 and Scope 2 emissions at 5,261,000 kg CO2e and 7,253,000 kg CO2e, respectively. Fuji Pharma has set ambitious climate commitments, aiming for carbon neutrality by 2050. In the near term, the company has committed to reducing absolute Scope 1 and Scope 2 greenhouse gas emissions by 42% by FY2030, using FY2022 as the baseline. Additionally, they plan to reduce Scope 3 emissions from purchased goods and services by 25% within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are designed to support the global goal of limiting temperature rise to 1.5°C.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 5,261,000 | 0,000,000 |
| Scope 2 | 7,253,000 | 0,000,000 |
| Scope 3 | - | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Fuji Pharma Co is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
